IP Library Granted Patent US 7,838,225
Granted Patent B2
US 7,838,225 · App. 11/473,828 · Granted Nov 23, 2010

Methods for detection of a target nucleic acid by forming a cleavage structure using a reverse transcriptase

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,838,225
App. No.
11/473,828
Granted
Nov 23, 2010
Kind
B2
Abstract

The invention relates to and methods for generating a signal indicative of the presence of a target nucleic acid in a sample. The compositions and methods include a reverse transcriptase, a nuclease, an upstream primer and downstream probe.

Claims (26)

1. A method for detecting a target nucleic acid sequence in a sample comprising, mixing an upstream primer, a downstream probe, wherein the downstream probe comprises a 5′ region and a 3′ region, wherein the 3′ region is at least partially complementary to the target nucleic acid and the 5′ region forms a flap, a reverse transcriptase, a cleavage agent and a target nucleic acid under conditions which are permissive for the steps of

(i) annealing of the upstream primer and downstream probe,

(ii) extending the upstream primer wherein the reverse transcriptase synthesizes a primer extension product and forms a cleavage structure with the downstream probe, and

(iii) cleaving the cleavage structure with the cleavage agent to generate a detectable signal

(iv) detecting and/or measuring said detectable signal, wherein detecting and/or measuring of said detectable signal is indicative of the presence of said target nucleic acid.

2. The method of claim 1 , wherein the cleavage agent is a FEN nuclease.

3. The method of claim 1 , wherein the reverse transcriptase is thermostable.

4. The method of claim 1 wherein the reverse transcriptase is selected from the group consisting of: Moloney Murine Leukemia Virus (M-MLV) RT, Human Immunodeficiency Virus (HIV) RT, Avian Sarcoma-Leukosis Virus (ASLV) RT, Rous Sarcoma Virus (RSV) RT, Avian Myeloblastosis Virus (AMV) RT, Avian Erythroblastosis Virus (AEV), Helper Virus MCAV RT, Avian Myelocytomatosis Virus, MC29 Helper Virus MCAV RT, Avian Reticuloendotheliosis Virus (REV-T), Helper Virus REV-A RT, Avian Sarcoma Virus, UR2 Helper Virus UR2AV RT, Avian Sarcoma Virus, Y73 Helper Virus YAV RT, Rous Associated Virus (RAV) RT, and Myeloblastosis Associated Virus (MAV) RT.

5. The method of claim 2 , wherein the FEN nuclease is thermostable.

6. The method of claim 2 , wherein the FEN nuclease is a flap-specific nuclease.

7. A method of detecting a target nucleic acid, comprising:

(a) providing:

an upstream primer that is at least partially complementary to a first region of a target nucleic acid, and

a downstream oligonucleotide comprising a 5′ region and a 3′ region, wherein the 3′ region is at least partially complementary to a second region of the target nucleic acid;

(b) mixing the target nucleic acid and the upstream primer and downstream oligonucleotide under conditions which permit formation of a duplex between the target nucleic acid and the upstream primer and the 3′ region of the downstream oligonucleotide;

(c) subjecting the duplex to a reverse transcriptase polymerization activity under conditions which permit extension of the upstream primer by polymerization of a DNA strand complementary to a length of the extension region sufficient to form a cleavage structure;

(d) providing a cleavage agent under conditions such that cleavage of the cleavage structure occurs at a site located within the downstream oligonucleotide in a manner dependent upon the formation of the cleavage structure, thereby permitting cleavage of the downstream oligonucleotide;

(e) detecting the cleavage of the downstream oligonucleotide, wherein detecting said cleavage of said downstream oligonucleotide is indicative of the presence of said target nucleic acid.

8. The method of claim 7 , wherein the primer and the downstream oligonucleotide hybridize to non-overlapping regions of the target nucleic acid.

9. The method of claim 7 , wherein the cleavage agent is a FEN nuclease.

10. The method of claim 7 , wherein the reverse transcriptase polymerization activity comprises strand displacement activity.

11. The method of claim 7 , wherein the method is carried out isothermally.

12. The method of claim 7 , wherein the reverse transcriptase is selected from the group consisting of: Moloney Murine Leukemia Virus (M-MLV) RT, Human Immunodeficiency Virus (HIV) RT, Avian Sarcoma-Leukosis Virus (ASLV) RT, Rous Sarcoma Virus (RSV) RT, Avian Myeloblastosis Virus (AMV) RT, Avian Erythroblastosis Virus (AEV), Helper Virus MCAV RT, Avian Myelocytomatosis Virus, MC29 Helper Virus MCAV RT, Avian Reticuloendotheliosis Virus (REV-T), Helper Virus REV-A RT, Avian Sarcoma Virus, UR2 Helper Virus UR2AV RT, Avian Sarcoma Virus, Y73 Helper Virus YAV RT, Rous Associated Virus (RAV) RT, and Myeloblastosis Associated Virus (MAV) RT.

13. The method of claim 7 , wherein the reverse transcriptase polymerization activity polymerizes nucleotides complementary to a length of extension region sufficient to form a cleavage structure, the polymerized complementary nucleic acid is adjacent at its 3′ end to the downstream oligonucleotide in the duplex.

14. The method of claim 7 , wherein the reverse transcriptase activity polymerizes nucleotides complementary to a length of extension region sufficient to form a cleavage structure, the length of the extension region is a length such that the extension region is fully duplex nucleic acid.

15. The method of claim 7 , wherein the 5′ region of the downstream probe forms a 5′ flap.

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO DIRECT RADIOGRAPHY CORP.; CYTYC CORPORATION, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO BIOLUCENT, LLC; CYTYC SURGICAL PRODUCTS, LLC, AS SUCCESSOR-BY-CONVERSION TO CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; GEN-PROBE INCORPORATED, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.
Reel/Frame 075566/0039 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE. Recorded Nov 9, 2017
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 044727/0529 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Nov 9, 2017
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 044432/0565 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE REEL/FRAME 028810/0745 Recorded Jun 4, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 035820/0239 →
SECURITY AGREEMENT Recorded Aug 1, 2012
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 028810/0745 →
TERMINATION OF PATENT SECURITY AGREEMENTS AND RELEASE OF SECURITY INTERESTS Recorded Aug 26, 2010
From: GOLDMAN SACHS CREDIT PARTNERS, L.P., AS COLLATERAL AGENT
To: HOLOGIC, INC.; R2 TECHNOLOGY, INC.; SUROS SURGICAL SYSTEMS, INC.; BIOLUCENT, LLC; DIRECT RADIOGRAPHY CORP.; CYTYC SURGICAL PRODUCTS II LIMITED PARTNERSHIP; CYTYC SURGICAL PRODUCTS LIMITED PARTNERSHIP; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS III, INC.; CYTYC PRENATAL PRODUCTS CORP.; THIRD WAVE TECHNOLOGIES, INC.
Reel/Frame 024892/0001 →
EIGHTH SUPPLEMENT TO PATENT SECURITY AGREEMENT Recorded Mar 26, 2009
From: CYTYC CORPORATION; HOLOGIC, INC.
To: GOLDMAN SACHS CREDIT PARTNERSL.P.
Reel/Frame 022456/0947 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2008
From: STRATAGENE CALIFORNIA
To: HOLOGIC INC.
Reel/Frame 021976/0268 →